Casdin Partners Master Fund, L.P. sold LAB
March 18, 2024 · Form 4 insider transaction
Casdin Partners Master Fund, L.P. sold 89,446 shares of Standard BioTools Inc. at $2.75 per share, a transaction worth $246.0K. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share.; The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.